Literature DB >> 6976938

Serum antibody responses to Pneumocystis carinii among different strains of normal and athymic mice.

P D Walzer, M E Rutledge.   

Abstract

Pneumocystis carinii infection was produced in normal mice by the administration of corticosteroids and in athymic mice by the transmission of exogenous mouse- or rat-derived organisms. Serum antibodies to P. carinii, measured by an indirect fluorescent-antibody technique, were found in five of six strains of normal mice. Although antibody titers varied widely among the control and steroid-treated mice, they were inversely proportional to the intensity of P. carinii infection in the lungs. In sequential studies, antibody titers were low during steroid administration but rose with steroid withdrawal. Antibodies were mainly of the immunoglobulin G (IgG) class; IgM antibodies also occurred, but IgA antibodies were rare. nu/nu mice rarely produced serum antibodies to P. carinii despite the fact that one strain was sensitive and the other was resistant to exogenous infection. nu/+ mice produced specific antibodies to rat and mouse P. carinii which were primarily IgG. Thus, the host produces antibodies to P. carinii which are mainly IgG and T-cell dependent; yet, these antibodies do not appear to be important in susceptibility or resistance to P. carinii infection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6976938      PMCID: PMC351086          DOI: 10.1128/iai.35.2.620-626.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Pneumocystis carinii pneumonia and primary immune deficiency diseases of infancy and childhood.

Authors:  P D Walzer; M G Schultz; K A Western; J B Robbins
Journal:  J Pediatr       Date:  1973-03       Impact factor: 4.406

2.  Corticosteroids and lymphoid cells.

Authors:  H N Claman
Journal:  N Engl J Med       Date:  1972-08-24       Impact factor: 91.245

3.  Pneumocystis carinii pneumonia in a hospital for children. Epidemiologic aspects.

Authors:  D R Perera; K A Western; H D Johnson; W W Johnson; M G Schultz; P V Akers
Journal:  JAMA       Date:  1970-11-09       Impact factor: 56.272

4.  Latent Pneumocystis infection of rats, relapse, and chemotherapy.

Authors:  J K Frenkel; J T Good; J A Shultz
Journal:  Lab Invest       Date:  1966-10       Impact factor: 5.662

5.  Protein-calorie malnutrition. A host determinant for Pneumocystis carinii infection.

Authors:  W T Hughes; R A Price; F Sisko; W S Havron; A G Kafatos; M Schonland; P M Smythe
Journal:  Am J Dis Child       Date:  1974-07

6.  Studies of morphology and immunofluorescence of Pneumocystis carinii.

Authors:  H K Kim; W T Hughes; S Feldman
Journal:  Proc Soc Exp Biol Med       Date:  1972-10

7.  A preliminary report of an indirect fluorescent antibody test for detecting antibodies to cysts of Pneumocystis carinii in human sera.

Authors:  L Norman; I G Kagan
Journal:  Am J Clin Pathol       Date:  1972-08       Impact factor: 2.493

8.  Some observations on the serology of Pneumocystis carinii infections in the United States.

Authors:  L Norman; I G Kagan
Journal:  Infect Immun       Date:  1973-09       Impact factor: 3.441

9.  Direct fluorescent-antibody method for the diagnosis of Pneumocystis carinii pneumonitis from sputa or tracheal aspirates from humans.

Authors:  S K Lim; W C Eveland; R J Porter
Journal:  Appl Microbiol       Date:  1974-01

10.  Development and evaluation of a direct fluorescent antibody method for the diagnosis of Pneumocystis carinii infections in experimental animals.

Authors:  S K Lim; W C Eveland; R J Porter
Journal:  Appl Microbiol       Date:  1973-11
View more
  10 in total

1.  Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs.

Authors:  P D Walzer; J Runck; P Steele; M White; M J Linke; C L Sidman
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 2.  Colonization by Pneumocystis jirovecii and its role in disease.

Authors:  Alison Morris; Karen A Norris
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

3.  Pneumocystis carinii: oxygen uptake, antioxidant enzymes, and susceptibility to oxygen-mediated damage.

Authors:  E L Pesanti
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

4.  Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice.

Authors:  J B Roths; C L Sidman
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

5.  Pneumocystis carinii organisms obtained from rats, ferrets, and mice are antigenically different.

Authors:  N L Bauer; J R Paulsrud; M S Bartlett; J W Smith; C E Wilde
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

6.  Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice.

Authors:  J B Roths; C L Sidman
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

7.  Cellular and humoral immune responses of mice subclinically infected with Pneumocystis carinii.

Authors:  T Furuta; K Ueda; K Fujiwara; K Yamanouchi
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

8.  Predisposing factors in Pneumocystis carinii pneumonia: effects of tetracycline, protein malnutrition, and corticosteroids on hosts.

Authors:  P D Walzer; M LaBine; T J Redington; M T Cushion
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

9.  Outbreaks of Pneumocystis carinii pneumonia in colonies of immunodeficient mice.

Authors:  P D Walzer; C K Kim; M J Linke; C L Pogue; M J Huerkamp; C E Chrisp; A V Lerro; S K Wixson; E Hall; L D Shultz
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

10.  Properties of the major antigens of rat and human Pneumocystis carinii.

Authors:  M J Linke; M T Cushion; P D Walzer
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.